These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 22646772)
21. Practical management of classical myeloproliferative disorder patients: a clinician's guide. Mesa RA Future Oncol; 2006 Aug; 2(4):515-24. PubMed ID: 16922618 [TBL] [Abstract][Full Text] [Related]
22. The recent advances in classic BCR-ABL-negative myeloproliferative disorders. Tefferi A Clin Adv Hematol Oncol; 2007 Feb; 5(2):113-5. PubMed ID: 17344799 [No Abstract] [Full Text] [Related]
23. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation]. Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592 [TBL] [Abstract][Full Text] [Related]
24. [Treatment of myeloproliferative neoplasms other than chronic leukemia]. Ohyashiki JH Nihon Rinsho; 2009 Oct; 67(10):1964-8. PubMed ID: 19860198 [TBL] [Abstract][Full Text] [Related]
25. Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia. Nakata Y Hiroshima J Med Sci; 1993 Jun; 42(2):67-71. PubMed ID: 8253600 [TBL] [Abstract][Full Text] [Related]
26. JAK2 mutations and clinical practice in myeloproliferative neoplasms. Tefferi A Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973 [TBL] [Abstract][Full Text] [Related]
27. New insights into the pathogenesis and treatment of chronic myeloproliferative disorders. Mesa RA Curr Opin Hematol; 2008 Mar; 15(2):121-6. PubMed ID: 18300758 [TBL] [Abstract][Full Text] [Related]
28. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders. Pikman Y; Levine RL Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464 [TBL] [Abstract][Full Text] [Related]
30. Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation. Ammatuna E; Ottone T; Zaza S; Lavorgna S; Grillo R; Curzi P; Panetta P; Federici G; Amadori S; Lo-Coco F Ann Hematol; 2007 May; 86(5):355-61. PubMed ID: 17285276 [TBL] [Abstract][Full Text] [Related]
31. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms? Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540 [TBL] [Abstract][Full Text] [Related]
32. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture. Tefferi A Leuk Res; 2012 Dec; 36(12):1481-9. PubMed ID: 22917768 [TBL] [Abstract][Full Text] [Related]
33. [Correlation between JAK2-V617F mutations and variation of peripheral blood cells among BCR/ABL-negative MPD patients]. Ye YX; Song XB; Zhou Y; Ying BW; Lu XJ Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Oct; 29(5):582-6. PubMed ID: 23042399 [TBL] [Abstract][Full Text] [Related]
39. Correlation of JAK2 V617F mutant allele quantitation with clinical presentation and type of chronic myeloproliferative neoplasm. Malysz J; Crisan D Ann Clin Lab Sci; 2009; 39(4):345-50. PubMed ID: 19880761 [TBL] [Abstract][Full Text] [Related]
40. Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives. Krecak I; Verstovsek S; Lucijanic M Ann Hematol; 2024 May; 103(5):1513-1523. PubMed ID: 37665349 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]